^
BIOMARKER:

EGFR overexpression

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive: B - Late Trials
EGFR overexpression
NSCLC
gefitinib
Sensitive: B - Late Trials
EGFR overexpression
NSCLC
necitumumab
Sensitive: C2 – Inclusion Criteria
EGFR overexpression
SCCHN
cetuximab
Sensitive: C2 – Inclusion Criteria
EGFR overexpression
Gastric Cancer
ASLAN001
Sensitive: C3 – Early Trials
EGFR overexpression
CRC
cetuximab
Sensitive: C3 – Early Trials
EGFR overexpression
Gastric Cancer
GC-1118A
Sensitive: C3 – Early Trials
EGFR overexpression
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR overexpression
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR overexpression
HCC
gefitinib + lenvatinib
Sensitive: C3 – Early Trials
EGFR overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
EGFR overexpression
Osteosarcoma
gemcitabine
Resistant: D – Preclinical
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABBV-321
Sensitive: D – Preclinical
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABT-414
Sensitive: D – Preclinical
EGFR overexpression
GBM
ONC201
Resistant: D – Preclinical
EGFR overexpression
Lung Cancer
cetuximab + avelumab
Sensitive: D – Preclinical
EGFR overexpression
Gastric Cancer
cetuximab
Sensitive: D – Preclinical
EGFR overexpression
NSCLC
cetuximab
Sensitive: D – Preclinical
EGFR overexpression
Breast Cancer
vandetanib
Sensitive: D – Preclinical
EGFR overexpression
Esophageal Squamous Cell Carcinoma
nimotuzumab
Sensitive: D – Preclinical